Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B

Merck & Co., Inc.

2021-Q3 EPS reported $3.66 revenue$35,183,000,000

Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).
Keytruda sales $4.5B (+22%); Gardasil $2.0B (+68%); Animal Health $1.4B (+16%).
Raises FY2021 revenue guidance to $47.4B–$47.9B; Non-GAAP EPS to $5.65–$5.70.
Agreement to acquire Acceleron Pharma for $180/share (~$11.5B); expected close Q4 2021.
Submitted EUA for molnupiravir (oral COVID-19 treatment) based on positive Phase 3 data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.